Sanofi
The purpose of this retrospective medical record review is to describe the real-world clinical effectiveness of dupilumab with patients in the United Kingdom with severe asthma.
Asthma
No intervention
Participants initiating treatment with dupilumab in the UK between 5th July 2019 and 12th August 2021 will be included in the study record review, permitting participation in research and if medical records are available for review. No intervention will be administered in this clinical trial. Data will be collected from hospital medical records and other hospital databases.
Study Type : | OBSERVATIONAL |
Estimated Enrollment : | 144 participants |
Official Title : | Real-world Experience of Dupilumab for the Treatment of Severe Asthma in the United Kingdom: a Retrospective Study |
Actual Study Start Date : | 2023-04-19 |
Estimated Primary Completion Date : | 2024-10-15 |
Estimated Study Completion Date : | 2024-10-15 |
Information not available for Arms and Intervention/treatment
Ages Eligible for Study: | 18 Years |
Sexes Eligible for Study: | ALL |
Accepts Healthy Volunteers: |
Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.
Not yet recruiting
Sanofi-Aventis, France
Chilly-Mazarin, France, 91380